New government drug repurposing programs: Opportunities and uncertainties

Johnathan Liddicoat; Ashleigh  Hamidzadeh; Kathleen Liddell; Marco   Schito; David  Simon; Mateo Aboy; Timo Minssen

doi:10.1126/scitranslmed.adl0998

New government drug repurposing programs: Opportunities and uncertainties

Johnathan Liddicoat^*, Ashleigh Hamidzadeh , Kathleen Liddell, Marco Schito, David Simon, Mateo Aboy, Timo Minssen

^*Corresponding author af dette arbejde

Centeret for Avancerede Studier i Biovidenskablig Innovationsret

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

1 Citationer (Scopus)

Abstract

Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies

Originalsprog	Engelsk
Artikelnummer	eadl0998
Tidsskrift	Science Translational Medicine
Vol/bind	16
Udgave nummer	753
Antal sider	4
ISSN	1946-6234
DOI	https://doi.org/10.1126/scitranslmed.adl0998
Status	Udgivet - 2024

Bibliografisk note

Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.

Emneord

Det Juridiske Fakultet

Adgang til dokumentet

10.1126/scitranslmed.adl0998Licens: Ikke-specificeret

Citationsformater

@article{ecb193fe331840e1a11480d5d8ad6d2f,

title = "New government drug repurposing programs: Opportunities and uncertainties",

abstract = "Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies",

keywords = "Faculty of Law, Government Programs, drug R&D, new uses, drug repurposing, Public private partnership, Emperical legal studies",

author = "Johnathan Liddicoat and Ashleigh Hamidzadeh and Kathleen Liddell and Marco Schito and David Simon and Mateo Aboy and Timo Minssen",

note = "Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.",

year = "2024",

doi = "10.1126/scitranslmed.adl0998",

language = "English",

volume = "16",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "american association for the advancement of science",

number = "753",

}

TY - JOUR

T1 - New government drug repurposing programs

T2 - Opportunities and uncertainties

AU - Liddicoat, Johnathan

AU - Hamidzadeh , Ashleigh

AU - Liddell, Kathleen

AU - Schito, Marco

AU - Simon, David

AU - Aboy, Mateo

AU - Minssen, Timo

N1 - Liddicoat J, Hamidzadeh A, Liddell K, Schito M, Simon D, Aboy M, Minssen T. New government drug repurposing programs: Opportunities and uncertainties. Sci Transl Med. 2024 Jun 26;16(753):eadl0998. doi: 10.1126/scitranslmed.adl0998. Epub 2024 Jun 26. PMID: 38924430.

PY - 2024

Y1 - 2024

N2 - Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies

AB - Drug repurposing can be cheaper and faster than developing new compounds. Yet, it remains underused, par-tially because of regulatory and intellectual property challenges. Policy-makers in the United States and Europehave created seven drug development programs that aim to overcome these challenges using a variety ofdifferent strategies

KW - Faculty of Law

KW - Government Programs

KW - drug R&D

KW - new uses

KW - drug repurposing

KW - Public private partnership

KW - Emperical legal studies

U2 - 10.1126/scitranslmed.adl0998

DO - 10.1126/scitranslmed.adl0998

M3 - Journal article

C2 - 38924430

VL - 16

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 753

M1 - eadl0998

ER -